75Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Ukraine
Neuroscience Intelligence
Ukraine neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #45 of 50 · Data maturity A · Research score 27.6 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
13Recruiting trials
8Publications
4Institutions
Executive interpretation
Ukraine ranks #45 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC106 recruiting
Boehringer Ingelheim50 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.40 recruiting
GlaxoSmithKline30 recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.30 recruiting
Sumitomo Pharma America, Inc.30 recruiting
Genzyme, a Sanofi Company30 recruiting
Celgene20 recruiting
ACADIA Pharmaceuticals Inc.20 recruiting
Forest Laboratories20 recruiting
Disease activity
Epilepsy18trials
Parkinsons17trials
Multiple Sclerosis9trials
Schizophrenia9trials
Alzheimers6trials
Depression5trials
Other Neurology2trials
Autism2trials
Stroke1trials
Bipolar Disorder1trials
Research institutions
Shupyk National Healthcare University of UkraineOpenAlexlinked institution
Institute of Neurology, Psychiatry and NarcologyOpenAlexlinked institution
National Academy of Medical Sciences of UkraineOpenAlexlinked institution
Vasyl Stefanyk Carpathian National UniversityOpenAlexlinked institution
Clinical evidence trail
NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RECRUITING
NCT07067463A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06788912Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)RECRUITING
NCT06604507Feasibility of Using an App for Managing Phantom Limb Pain Associated with Combat Injury in Ukraine (PAMELA)NOT_YET_RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05123703A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)ACTIVE_NOT_RECRUITING
NCT04879628Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT04544436A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)ACTIVE_NOT_RECRUITING
NCT04165798KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)RECRUITING
Research evidence trail
PUBMEDEfficacy and cardiovascular safety of lasmiditan in patients with cardiovascular risk factors: A systematic review and meta-analysis with updated synthesis of triptan safety data.2026-10-01
PUBMEDNeurocognitive consequences of blast injuries in military personnel with mild traumatic brain injury: evaluation with the ImPACT quick test.2026-09-22
PUBMEDAge- and sex-dependent effects of single prolonged stress on behavioral, hematological, and oxidative stress parameters in C57BL/6J mice.2026-09-11
PUBMEDAn Augmented Reality-Based Concept for Anchor-Free Assessment of Tremor-Related Hand Movement Patterns.2026-09-07
PUBMEDCeftriaxone has a similar effect on astrocytic and neuronal GLT-1 distribution after mild traumatic brain injury.2026-07-16
PUBMEDMaternal microbiota and fetal brain development: a multidisciplinary review of cognitive, neurological, and metabolic outcomes.2026-01-01
OPENALEXGlutathione Homeostasis and Functions: Potential Targets for Medical Interventions2012-02-28
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.